Skip to main content
For Healthcare Professionals
Homepage Banner

Novel mechanism of action

JASCAYD® is a preferential PDE4B inhibitor with antifibrotic, immunomodulatory, and vascular effects5,6
Discover how JASCAYD® works

Simple dosing

The recommended dose is 18 mg twice daily7,*,†
Check dosing information

Helpful resources

Share JASCAYD® resources with your patients and your practice
Discover and download

*Based on individual patient tolerability of certain adverse reactions (diarrhea, weight loss), the dosage may be reduced to 9 mg twice daily.7

†The dosage of JASCAYD® must be reduced to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors. The dosage of JASCAYD® must NOT be reduced to 9 mg twice daily when used concomitantly with strong or moderate CYP3A inducers (and pirfenidone).7

References

  1. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2025;392(22):2193-2202.

  2. Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study. Published September 16, 2024. Accessed February 20, 2026. https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/nerandomilast-primary-endpoint-phase-3-fibroneer-ild-pulmonary-fibrosis

  3. Boehringer Ingelheim Pharmaceuticals, Inc. FDA approves OFEV® as first treatment for chronic fibrosing ILDs with a progressive phenotype. Published March 9, 2020. Accessed February 20, 2026. https://www.boehringer-ingelheim.us/press-release/fda-approves-ofev-first-treatment-chronic-fibrosing-ilds-progressive-phenotype

  4. OFEV® Summary of Product Characteristics UAE; June 2025.

  5. Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol. 2022;13:838449.

  6. Reininger D, Wolf F, Mayr CH, et al. Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am J Respir Cell Mol Biol. 2025;73(5):700-712.

  7. JASCAYD® UAE Local SmPC; May 2026.

MLR ID: PC-AE-102896
Expiry Date: 10/05/2028